albumin-bound docetaxel + SG001

This drug is a **combination therapy** consisting of albumin-bound docetaxel and SG001. Albumin-bound docetaxel (HB1801) is a nanoparticle formulation of the antineoplastic agent docetaxel, designed to improve drug delivery and reduce hypersensitivity reactions compared to conventional docetaxel. SG001 is a fully human monoclonal antibody that targets the **programmed cell death 1 (PD-1)** receptor, functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. This combination is in early stage (Phase 1/2) clinical trials for the treatment of locally advanced unresectable esophageal squamous carcinoma, used together with cisplatin and radiotherapy. HB1801 is developed to improve the pharmacokinetics and safety profile of docetaxel, while SG001 adds immunotherapeutic antitumor activity through PD-1 blockade[1][3].

Other names

Docetaxel for Injection (Albumin-bound) + SG001Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection (for SG001)